David F. Penson, MD, MPH, MMHC, discusses ongoing research in prostate cancer.
David F. Penson, MD, MPH, MMHC
Advertisement
Articles by David F. Penson, MD, MPH, MMHC
David F. Penson, MD, MPH, MMHC, discusses the importance of maintaining quality of life for patients treated with androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer.
David F. Penson, MD, MPH, MMHC, discusses questions regarding next-generation androgen receptor (AR) inhibitors in prostate cancer.
David F. Penson, MD, MPH, MMHC, discusses treatment selection in patients with metastatic hormone-sensitive prostate cancer.
Advertisement
Latest Updated Articles
Dr. Penson on Questions Regarding Next-Generation AR Inhibitors in Prostate CancerPublished: January 25th 2020 | Updated:
Dr. Penson on Maintaining QoL With AR Inhibitors in Nonmetastatic CRPCPublished: January 25th 2020 | Updated:
Dr. Penson on Ongoing Research in Prostate CancerPublished: May 15th 2020 | Updated:
Dr. Penson on Treatment Selection in Metastatic Hormone-Sensitive Prostate CancerPublished: November 22nd 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5